Onkologie. 2022:16(4):222-225 | DOI: 10.36290/xon.2022.042

Rapid, deep and long lasting respnose to cetuximab

Marián Liberko1, 2, Renata Soumarová1, 2
1 Onkologická klinika FNKV, Praha
2 3. lékařská fakulta Univerzity Karlovy, Praha

We describe a case-report of patient with massively disseminated mCRC to the liver with incipient signs of liver failure. Combined treatment with use of chemotherapy + anti-EGFR antibody lead to rapid, deep and long lasting response.

Keywords: mCRC, liver metastases, liver failure, cetuximab.

Accepted: August 22, 2022; Published: August 24, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M, Soumarová R. Rapid, deep and long lasting respnose to cetuximab. Onkologie. 2022;16(4):222-225. doi: 10.36290/xon.2022.042.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44-70. doi: 10.1093/annonc/mdx738. PMID: 29155929. Go to original source... Go to PubMed...
    2. Heinemann V, Stintzing S, Modest DP, et al. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer. 2015;51(14):1927-1936. doi: 10.1016/j.ejca.2015.06.116. Epub 2015 Jul 15. PMID: 26188850. Go to original source... Go to PubMed...
    3. Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713-1729. doi: 10.1093/annonc/mdx175. PMID: 28407110; PMCID: PMC6246616. Go to original source... Go to PubMed...
    4. Ramírez-Maldonado E, García-Pérez R, Ferrer-Fàbrega J, et al. Missing colorectal liver metastases: the surgical challenge. Langenbecks Arch Surg. 2021;406(7):2163-2175. doi: 10.1007/s00423-021-02297-4. Epub 2021 Sep 30. PMID: 34590190. Go to original source... Go to PubMed...
    5. Kanemitsu Y, Shitara K, Mizusawa J, et al. JCOG Colorectal Cancer Study Group. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial. J Clin Oncol. 2021;39(10):1098-1107. doi: 10.1200/JCO.20.02447. Epub 2021 Feb 9. PMID: 33560877; PMCID: PMC8078424. Go to original source... Go to PubMed...
    6. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-1417. doi: 10.1056/NEJMoa0805019. PMID: 19339720. Go to original source... Go to PubMed...
    7. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065-1075. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. PMID: 25088940. Go to original source... Go to PubMed...
    8. Mayer RJ, Van Cutsem E, Falcone A, et al. RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909-1919. doi: 10.1056/NEJMoa1414325. PMID: 25970050. Go to original source... Go to PubMed...
    9. Grothey A, Van Cutsem E, Sobrero A, et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22. PMID: 23177514. Go to original source... Go to PubMed...
    10. Cremolini C, Rossini D, Dell'Aquila E, et al. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol. 2019;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. PMID: 30476968; PMCID: PMC6439839. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.